Vascular brachytherapy revisited for in-stent restenosis in the drug-eluting stent era

Current status and future perspective

Xiong Jie Li, Seung-Woon Rha, Sunil P. Wani, Lin Wang, Kanhaiya L. Poddar, Dong Joo Oh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Intracoronary brachytherapy has reached its maturity. The technology is improved to be simple, operator-friendly and cost-effective. DES, especially next generation DES surely has a bright future and with the recent trials seems to be on the verge of replacing VBT in ISR. The simplicity and availability of DES have made more clinical widespread applicability and acceptance to DES in every subset of diseases. However, the ISR could not be completely eliminated even with the next generation DES and there are newly developing complications associated with DES such as increasing stent thrombosis due to delayed endothelialization, aneurysm formation, late stent malapposition, DES-associated endothelial dysfunction and clinically significant vasospasm. We can conclude that until the long-term safety and efficacy of DES is surely proved, VBT will continue to be utilized for treatment of ISR and difficult subsets mentioned earlier especially in diffuse long lesions and in patients with repeat DES failure. VBT is definitely a step ahead in the treatment of calcific and vein graft disease. Further simplification of the administration of VBT procedure will help the interventional cardiologists to embark on this therapy more and more. Balloon filled radioactive elements may be a competitive option to DES because it permits ease of administration and optimization of the length of radiation source which is not possible with DES. In de novo lesions DES has surpassed VBT thus reducing its need in the real world interventional practice. Future of coronary intervention will reduce the need for coronary bypass surgery as much as possible. Although the utilization of VBT has dramatically reduced after the introduction of DESs, VBT has been used in nearly 500 catheterization laboratories in United States and has treated 40 000 patients with ISR per annum for several years. Cost effective analysis performed from gamma-1 and INHIBIT studies has shown that though initial cost of treatment is high, it will offset this in the long run due to decrease in the TLR and bypass surgery. Now time will tell us whether VBT will remain a tool to treat DES failures or vice versa. Treatment of coronary atherosclerosis will see a dynamic change in the next 5 years. Progress in antiplatelet agents, pleuripotent agents such as statins, thiozolidenediones, fibrates on the pharmacologic side, advancements in cell therapy for enhanced vascular healing and technologic developments in stent design, drug coated and DESs/balloons are sure to impact on future therapy of coronary atherosclerosis. However, despite all these developments, every therapeutic strategy may have its own limitations. With the complete understanding of various issues and problems, VBT should be considered as a back-up strategy for the shortcomings of other newly developing techniques.

Original languageEnglish
Pages (from-to)2174-2179
Number of pages6
JournalChinese Medical Journal
Volume122
Issue number18
DOIs
Publication statusPublished - 2009 Sep 20

Fingerprint

Drug-Eluting Stents
Brachytherapy
Stents
Blood Vessels
Coronary Artery Disease
Radioactive Elements
Therapeutics
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Costs and Cost Analysis
Platelet Aggregation Inhibitors
Cell- and Tissue-Based Therapy
Catheterization
Health Care Costs
Aneurysm
Veins
Thrombosis
Radiation
Technology
Transplants

Keywords

  • Brachytherapy
  • Drug-eluting stent
  • Percutaneous coronary intervention
  • Restenosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vascular brachytherapy revisited for in-stent restenosis in the drug-eluting stent era : Current status and future perspective. / Li, Xiong Jie; Rha, Seung-Woon; Wani, Sunil P.; Wang, Lin; Poddar, Kanhaiya L.; Oh, Dong Joo.

In: Chinese Medical Journal, Vol. 122, No. 18, 20.09.2009, p. 2174-2179.

Research output: Contribution to journalArticle

Li, Xiong Jie ; Rha, Seung-Woon ; Wani, Sunil P. ; Wang, Lin ; Poddar, Kanhaiya L. ; Oh, Dong Joo. / Vascular brachytherapy revisited for in-stent restenosis in the drug-eluting stent era : Current status and future perspective. In: Chinese Medical Journal. 2009 ; Vol. 122, No. 18. pp. 2174-2179.
@article{00110500ac6d4f4a917841d0b198d25e,
title = "Vascular brachytherapy revisited for in-stent restenosis in the drug-eluting stent era: Current status and future perspective",
abstract = "Intracoronary brachytherapy has reached its maturity. The technology is improved to be simple, operator-friendly and cost-effective. DES, especially next generation DES surely has a bright future and with the recent trials seems to be on the verge of replacing VBT in ISR. The simplicity and availability of DES have made more clinical widespread applicability and acceptance to DES in every subset of diseases. However, the ISR could not be completely eliminated even with the next generation DES and there are newly developing complications associated with DES such as increasing stent thrombosis due to delayed endothelialization, aneurysm formation, late stent malapposition, DES-associated endothelial dysfunction and clinically significant vasospasm. We can conclude that until the long-term safety and efficacy of DES is surely proved, VBT will continue to be utilized for treatment of ISR and difficult subsets mentioned earlier especially in diffuse long lesions and in patients with repeat DES failure. VBT is definitely a step ahead in the treatment of calcific and vein graft disease. Further simplification of the administration of VBT procedure will help the interventional cardiologists to embark on this therapy more and more. Balloon filled radioactive elements may be a competitive option to DES because it permits ease of administration and optimization of the length of radiation source which is not possible with DES. In de novo lesions DES has surpassed VBT thus reducing its need in the real world interventional practice. Future of coronary intervention will reduce the need for coronary bypass surgery as much as possible. Although the utilization of VBT has dramatically reduced after the introduction of DESs, VBT has been used in nearly 500 catheterization laboratories in United States and has treated 40 000 patients with ISR per annum for several years. Cost effective analysis performed from gamma-1 and INHIBIT studies has shown that though initial cost of treatment is high, it will offset this in the long run due to decrease in the TLR and bypass surgery. Now time will tell us whether VBT will remain a tool to treat DES failures or vice versa. Treatment of coronary atherosclerosis will see a dynamic change in the next 5 years. Progress in antiplatelet agents, pleuripotent agents such as statins, thiozolidenediones, fibrates on the pharmacologic side, advancements in cell therapy for enhanced vascular healing and technologic developments in stent design, drug coated and DESs/balloons are sure to impact on future therapy of coronary atherosclerosis. However, despite all these developments, every therapeutic strategy may have its own limitations. With the complete understanding of various issues and problems, VBT should be considered as a back-up strategy for the shortcomings of other newly developing techniques.",
keywords = "Brachytherapy, Drug-eluting stent, Percutaneous coronary intervention, Restenosis",
author = "Li, {Xiong Jie} and Seung-Woon Rha and Wani, {Sunil P.} and Lin Wang and Poddar, {Kanhaiya L.} and Oh, {Dong Joo}",
year = "2009",
month = "9",
day = "20",
doi = "10.3760/cma.j.issn.0366-6999.2009.18.019",
language = "English",
volume = "122",
pages = "2174--2179",
journal = "Chinese Medical Journal",
issn = "0366-6999",
publisher = "Chinese Medical Association",
number = "18",

}

TY - JOUR

T1 - Vascular brachytherapy revisited for in-stent restenosis in the drug-eluting stent era

T2 - Current status and future perspective

AU - Li, Xiong Jie

AU - Rha, Seung-Woon

AU - Wani, Sunil P.

AU - Wang, Lin

AU - Poddar, Kanhaiya L.

AU - Oh, Dong Joo

PY - 2009/9/20

Y1 - 2009/9/20

N2 - Intracoronary brachytherapy has reached its maturity. The technology is improved to be simple, operator-friendly and cost-effective. DES, especially next generation DES surely has a bright future and with the recent trials seems to be on the verge of replacing VBT in ISR. The simplicity and availability of DES have made more clinical widespread applicability and acceptance to DES in every subset of diseases. However, the ISR could not be completely eliminated even with the next generation DES and there are newly developing complications associated with DES such as increasing stent thrombosis due to delayed endothelialization, aneurysm formation, late stent malapposition, DES-associated endothelial dysfunction and clinically significant vasospasm. We can conclude that until the long-term safety and efficacy of DES is surely proved, VBT will continue to be utilized for treatment of ISR and difficult subsets mentioned earlier especially in diffuse long lesions and in patients with repeat DES failure. VBT is definitely a step ahead in the treatment of calcific and vein graft disease. Further simplification of the administration of VBT procedure will help the interventional cardiologists to embark on this therapy more and more. Balloon filled radioactive elements may be a competitive option to DES because it permits ease of administration and optimization of the length of radiation source which is not possible with DES. In de novo lesions DES has surpassed VBT thus reducing its need in the real world interventional practice. Future of coronary intervention will reduce the need for coronary bypass surgery as much as possible. Although the utilization of VBT has dramatically reduced after the introduction of DESs, VBT has been used in nearly 500 catheterization laboratories in United States and has treated 40 000 patients with ISR per annum for several years. Cost effective analysis performed from gamma-1 and INHIBIT studies has shown that though initial cost of treatment is high, it will offset this in the long run due to decrease in the TLR and bypass surgery. Now time will tell us whether VBT will remain a tool to treat DES failures or vice versa. Treatment of coronary atherosclerosis will see a dynamic change in the next 5 years. Progress in antiplatelet agents, pleuripotent agents such as statins, thiozolidenediones, fibrates on the pharmacologic side, advancements in cell therapy for enhanced vascular healing and technologic developments in stent design, drug coated and DESs/balloons are sure to impact on future therapy of coronary atherosclerosis. However, despite all these developments, every therapeutic strategy may have its own limitations. With the complete understanding of various issues and problems, VBT should be considered as a back-up strategy for the shortcomings of other newly developing techniques.

AB - Intracoronary brachytherapy has reached its maturity. The technology is improved to be simple, operator-friendly and cost-effective. DES, especially next generation DES surely has a bright future and with the recent trials seems to be on the verge of replacing VBT in ISR. The simplicity and availability of DES have made more clinical widespread applicability and acceptance to DES in every subset of diseases. However, the ISR could not be completely eliminated even with the next generation DES and there are newly developing complications associated with DES such as increasing stent thrombosis due to delayed endothelialization, aneurysm formation, late stent malapposition, DES-associated endothelial dysfunction and clinically significant vasospasm. We can conclude that until the long-term safety and efficacy of DES is surely proved, VBT will continue to be utilized for treatment of ISR and difficult subsets mentioned earlier especially in diffuse long lesions and in patients with repeat DES failure. VBT is definitely a step ahead in the treatment of calcific and vein graft disease. Further simplification of the administration of VBT procedure will help the interventional cardiologists to embark on this therapy more and more. Balloon filled radioactive elements may be a competitive option to DES because it permits ease of administration and optimization of the length of radiation source which is not possible with DES. In de novo lesions DES has surpassed VBT thus reducing its need in the real world interventional practice. Future of coronary intervention will reduce the need for coronary bypass surgery as much as possible. Although the utilization of VBT has dramatically reduced after the introduction of DESs, VBT has been used in nearly 500 catheterization laboratories in United States and has treated 40 000 patients with ISR per annum for several years. Cost effective analysis performed from gamma-1 and INHIBIT studies has shown that though initial cost of treatment is high, it will offset this in the long run due to decrease in the TLR and bypass surgery. Now time will tell us whether VBT will remain a tool to treat DES failures or vice versa. Treatment of coronary atherosclerosis will see a dynamic change in the next 5 years. Progress in antiplatelet agents, pleuripotent agents such as statins, thiozolidenediones, fibrates on the pharmacologic side, advancements in cell therapy for enhanced vascular healing and technologic developments in stent design, drug coated and DESs/balloons are sure to impact on future therapy of coronary atherosclerosis. However, despite all these developments, every therapeutic strategy may have its own limitations. With the complete understanding of various issues and problems, VBT should be considered as a back-up strategy for the shortcomings of other newly developing techniques.

KW - Brachytherapy

KW - Drug-eluting stent

KW - Percutaneous coronary intervention

KW - Restenosis

UR - http://www.scopus.com/inward/record.url?scp=70350588920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350588920&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.0366-6999.2009.18.019

DO - 10.3760/cma.j.issn.0366-6999.2009.18.019

M3 - Article

VL - 122

SP - 2174

EP - 2179

JO - Chinese Medical Journal

JF - Chinese Medical Journal

SN - 0366-6999

IS - 18

ER -